Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering

By afschroeder • March 20, 2026

Chen X, Mao Z, Kolawole EM, Persechino M, Jude KM, Ogishi M, Mo KC, McLaughlin J, Cheng D, Xiang X, Yang X, Gee C, Liu S, Yang A, Obenaus M, Wang N, Noguchi M, Stoyanova T, Lee JK, Good Z, Latorraca NR, Evavold BD, Witte ON, Garcia KC. Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering. Science. 2026 Mar 19;391(6791):eadx3162. doi: 10.1126/science.adx3162. Epub 2026 Mar 19. PMID: 41855322; PMCID: PMC13004167.

Tags: Hematology/Oncology, Publications

Related Posts

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

Razak A, Mahipal A, Diamond JR, Ribas A, Berlin JD, Azmi AS, Mark T, Walker CJ, Chai Y, Kashyap T, Gudi G, Naing A. First-in-Human[...]